| Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.Clin Cancer Res | PMID 37379430无 PMCID | 2023-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 37440217PMC10346505 | 2023-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.JAMA Oncol | PMID 37471075PMC10360005 | 2023-Sep-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Zuranolone for the Treatment of Postpartum Depression.Am J Psychiatry | PMID 37491938无 PMCID | 2023-Sep-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer.JAMA Otolaryngol Head Neck Surg | PMID 37498566PMC10375388 | 2023-Sep-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes Obes Metab | PMID 37264711无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes Obes Metab | PMID 37344954无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.Arthritis Care Res (Hoboken) | PMID 36722450无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.Bipolar Disord | PMID 36779257无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.J Thorac Cardiovasc Surg | PMID 36841745无 PMCID | 2023-Sep | 0.90 | This is an exploratory analysis of safety and tolerability by surgery type from the randomized phase III IMpower010 trial. While the record is from a randomized, phase III, oncology, human, drug-intervention trial, the abstract focuses solely on adverse event rates and does not present a primary or key secondary time-to-event efficacy analysis. | 待处理 |
| Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.Pediatr Res | PMID 36899125PMC10000353 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.Chest | PMID 37003355PMC11898224 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vertebroplasty versus bracing in acute vertebral compression fractures: A prospective randomized trial.Ann Phys Rehabil Med | PMID 37030247无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.J Gastrointest Cancer | PMID 37037952PMC10613141 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis.J Rheumatol | PMID 37061234无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.Arthritis Rheumatol | PMID 37098795无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of imiquimod in the management of lentigo maligna.J Eur Acad Dermatol Venereol | PMID 37114291无 PMCID | 2023-Sep | 0.85 | The trial is a phase III RCT in oncology (lentigo maligna) with a drug intervention, but it lacks a primary or key secondary time-to-event efficacy endpoint with reported time-to-event data (e.g., Kaplan-Meier, HR). The primary endpoint is surgical success, and secondary endpoints do not include reported time-to-event outcomes. | 待处理 |
| Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial.J Neurotrauma | PMID 37130044无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.Ophthalmol Retina | PMID 37179017无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).Lancet Infect Dis | PMID 37182534无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.J Am Acad Dermatol | PMID 37182701无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.J Eur Acad Dermatol Venereol | PMID 37184290无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.Int J Infect Dis | PMID 37211270无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: multicenter phase 3 double-blind randomized placebo-controlled trial (ViDiKids).Int J Infect Dis | PMID 37211272无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.Clin Pharmacol Ther | PMID 37212707无 PMCID | 2023-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).J Cancer Res Clin Oncol | PMID 37213030PMC10374776 | 2023-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).J Am Acad Dermatol | PMID 37230366无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.J Thorac Oncol | PMID 37236398无 PMCID | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.J Eur Acad Dermatol Venereol | PMID 37247226无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.J Neurotrauma | PMID 37279301PMC10460693 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.Am J Clin Dermatol | PMID 37300760PMC10460374 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.Lancet Infect Dis | PMID 37348519无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| TP53 Gain-of-Function Mutation is a Poor Prognostic Factor in High-Methylated Metastatic Colorectal Cancer.Clin Colorectal Cancer | PMID 37355363无 PMCID | 2023-Sep | 0.85 | The report is a biomarker/prognostic subgroup analysis from a phase III randomized trial. While it is oncology, human, randomized, phase III, and reports time-to-event results, it does not explicitly establish a drug-containing intervention in the provided abstract. The analysis itself is secondary/subgroup, not the primary trial result. | 待处理 |
| Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506).Breast Cancer Res Treat | PMID 37365483PMC10361883 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.Ann Oncol | PMID 37399894PMC10849465 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.J Infect | PMID 37406777无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prostration and the prognosis of death in African children with severe malaria.Int J Infect Dis | PMID 37414210PMC7618391 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates (Review).Oncol Rep | PMID 37449542PMC10394734 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Preoperative mechanical bowel preparation using conventional versus hyperosmolar polyethylene glycol-electrolyte lavage solution before laparoscopic resection for colorectal cancer (TLUMP test): a phase III, multicenter randomized controlled non-inferiority trial.J Gastroenterol | PMID 37462794无 PMCID | 2023-Sep | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.Lancet Haematol | PMID 37517413无 PMCID | 2023-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.Lancet HIV | PMID 37567205无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 37591293无 PMCID | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.J Clin Hypertens (Greenwich) | PMID 37614053PMC10497032 | 2023-Sep | 0.90 | The study is a Phase III randomized trial of a drug-containing triple combination therapy, but it is for hypertension (non-oncology) and its primary efficacy endpoint is a change in blood pressure, not a time-to-event outcome like OS, PFS, DFS, etc., or Kaplan-Meier/HR analysis. | 待处理 |
| Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.Nat Med | PMID 37653342PMC10504066 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.Headache | PMID 37655536无 PMCID | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.Lancet Oncol | PMID 37657460无 PMCID | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.Target Oncol | PMID 37659025PMC10517884 | 2023-Sep | 0.95 | Meets all eligibility criteria: Phase 3 randomized trial in human oncology with a drug intervention and primary time-to-event efficacy endpoint. | 待处理 |
| Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic Breast Cancer: Analysis of ECOG-ACRIN E2112.J Natl Compr Canc Netw | PMID 37673107PMC10594540 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding Study.Clin Drug Investig | PMID 37682405PMC10514176 | 2023-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer.JCO Clin Cancer Inform | PMID 37713655PMC10569775 | 2023-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |